Market Intelligence

Specialist intelligence
for consumer healthcare.

Ingredient trends, regulatory signals, competitive moves, and white space analysis across three categories of consumer healthcare. Updated monthly. Prepared by Brendan Walsh, Principal.

Three verticals live  ·  Monthly cadence

June 2026
01
Dietary Supplements

Ingredient-level tracking across five high-growth segments. Evidence quality, velocity, and regulatory risk mapped monthly.

Segments tracked

Vitamins & minerals  ·  Gut health  ·  Nootropics  ·  Beauty & longevity  ·  Women's health

View Supplement Intelligence →
02
OTC & Consumer Health

Over-the-counter category tracking across four therapeutic segments. Claim landscape, reformulation signals, Rx-to-OTC pipeline, and competitive brand moves.

Segments tracked

Pain management  ·  Respiratory health  ·  Gastrointestinal  ·  Dermatological

View OTC Intelligence →
03
Oral Health

Ingredient and technology tracking across five oral health segments. Clinical evidence, regulatory positioning, and branded ingredient moves mapped monthly.

Segments tracked

Caries prevention  ·  Periodontal care  ·  Aesthetic / cosmetic  ·  Denture care  ·  Specialised

View Oral Health Intelligence →

Latest signals — Edition 03  ·  June 2026

Dietary Supplements
GLP-1 companion — Herbalife, Vitamin Shoppe, and My Companion Box all launch; category entering mainstream phase
Creatine (women) — second independent RCT confirms perimenopause cognitive and physical benefits
FTC Consumer Review Rule enforcement — supplement influencer disclosure and origin claims under heightened scrutiny
OTC & Consumer Health
Bemotrizinol final order expected June 2026 — first new FDA sunscreen active in 25 years; first-mover window open
Phenylephrine final order imminent — reformulation decisions unavoidable in H2 2026
Wegovy oral pill launched Jan 2026 — OTC GI companion addressable market expands materially
Oral Health
Fluoride-free toothpaste market $3.62B at 10.8% CAGR — nHAp is the core growth driver in 2026
GLP-1 dry mouth opportunity — two new oral GLP-1 approvals in 2026 expand xerostomia cohort; Biotene still uncontested
BioGaia Prodentis FRESH BREATH lozenge — oral probiotic category execution blueprint now visible

How the intelligence is produced

01
Primary source monitoring

FDA and FTC databases, ClinicalTrials.gov, PubMed, and regulatory dockets tracked monthly. Retail velocity from SPINS and trade press. No aggregator dependency.

02
Consultant framing

Every signal is translated into a concrete implication. Not what happened — what a brand, investor, or advisory client should do with it. Three decades of category experience in every observation.

03
Transparent data quality

Intelligence is directional secondary-source analysis unless otherwise noted. Where SPINS or primary data underpins a finding, it is cited. I distinguish signal from noise — and say so when I cannot tell the difference.

Three verticals. Monthly cadence. Built for the practitioner who needs to know what's moving — and why it matters.

Access the Intelligence Platform →
Ballymote Group Intelligence
Request access to continue

This intelligence is prepared for a select audience. Submit your details — Brendan will follow up directly.

✓
Access granted.

Unlocking now. Brendan will be in touch shortly.

Already have access? Contact Brendan directly.